NEX Health Intelligence has secured €1 million in pre-seed funding to accelerate the development and deployment of its artificial intelligence-powered infection intelligence platform across hospitals in the UK and internationally.
The round was led by Brighteye Ventures, with support from Adeline Arts & Science, AFI Ventures, Momentous Ventures, and Conception X Angel Syndicate. The capital will enable the UK-based healthtech company to expand its reach among NHS organisations and hospitals in Southeast Asia while advancing regulatory compliance and clinical safety validation.
Addressing Hospital Infection Challenges
Healthcare-associated infections represent a significant challenge for hospital systems globally, imposing substantial costs and patient safety risks. NEX Health Intelligence’s platform addresses this through AI-powered detection and prediction capabilities designed to help healthcare facilities identify infection patterns before they spread among vulnerable patient populations.
The platform has already demonstrated real-world impact, having supported infection safety across more than 40,000 patient admissions internationally. The company is currently working with multiple NHS organisations in the United Kingdom and expanding partnerships with hospitals across Southeast Asia.
The origin of the company’s mission traces to pandemic response work. “While supporting the NHS COVID-19 response, I realised the real challenge wasn’t just the number of admissions – it was how quickly infections spread between vulnerable patients already inside hospitals,” said Dr Ashleigh Myall, highlighting the core problem the platform targets.
Strategic Use of Funding
The investment will be deployed across three key areas: expanding the platform’s presence among NHS trusts and international hospital networks, conducting the regulatory and clinical safety work necessary for broader adoption, and generating clinical and economic evidence from active hospital deployments. This evidence generation will be critical for demonstrating the platform’s value proposition to healthcare decision-makers evaluating infection prevention solutions.
The funding arrival positions NEX Health Intelligence at a pivotal moment, as hospitals worldwide increasingly prioritise infection prevention infrastructure and seek technology solutions to reduce preventable healthcare-associated infections.
European Healthtech Momentum
This funding round reflects continued investor interest in European healthtech innovation focused on operational efficiency and patient safety. NEX Health Intelligence joins a growing cohort of UK-based medical technology companies attracting venture capital for solutions addressing clinical delivery challenges. The involvement of multiple specialist healthtech investors including Brighteye Ventures underscores sustained confidence in technology-driven approaches to hospital infection management and prevention, particularly among investors focused on the European healthcare sector.
BODY END